Anti-HER2 Antibody-drug Conjugate BAT8010

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) linked to the camptothecin analog exatecan, with potential antineoplastic activity. Upon administration of anti-HER2 ADC BAT8010, the anti-HER2 monoclonal antibody moiety targets and binds to HER2 expressed on tumor cells. Upon binding, internalization and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of HER2-expressing tumor cells. HER2, a receptor tyrosine kinase that is mutated or overexpressed in many tumor cell types, plays an important role in tumor cell proliferation and tumor vascularization.

**Synonyms:** - Anti-HER2 ADC BAT8010 - BAT 8010 - BAT-8010 - BAT8010